While tumor genetics contribute to therapies used to treat breast cancer and inform patient prognosis, modifications of histone proteins, which help organize the genetic material in cells into chromatin, can also influence therapeutic response and ultimately patient outcome. This evidence concerns the gene H2BC12L and breast cancer.